Atrium Therapeutics to Present Nonclinical Data on ATR 1072
The company will present data at AHA Scientific Sessions 2026 showing its investigational drug ATR 1072 reversed cardiac glycogen accumulation in a PRKAG2 syndrome mouse model, strengthening the rationale for its ongoing Phase 1/2 trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed